Table of Contents

Managing type 2 diabetes is already challenging, especially when other health conditions occur alongside it. Choosing between medications like Farxiga (dapagliflozin) and Ozempic (semaglutide) adds another layer of complexity.

Both drugs are widely prescribed. Ozempic is projected to become the world’s second best-selling drug by 2025, with estimated sales reaching $22.3 billion. Similarly, Farxiga was AstraZeneca’s top revenue-generating pharmaceutical product in 2024.

Yet, without clear guidance, patients may struggle to determine which medication best aligns with their health goals. This article provides a detailed comparison of Farxiga vs. Ozempic, covering their mechanisms of action, approved uses, and clinical outcomes.

Key Differences Between Farxiga and Ozempic

Parameters Farxiga Ozempic
US Average Retail Price $655 $1,203
Pharma Giant Price $119 $419
Active Ingredient Dapagliflozin Semaglutide
Drug Class Sodium-glucose Co-transporter 2 (SGLT2) Inhibitor Glucagon-like Peptide-1 (GLP-1) Receptor Agonist
Approved Indications
  • Help control blood sugar in adults and children (10+) with type 2 diabetes.
  • Lower the risk of heart-related death and hospital visits in adults with heart failure.
  • Reduce hospitalizations for heart failure in adults with type 2 diabetes who have heart disease or risk factors.
  • Slow kidney disease progression and reduce the risk of kidney failure, heart-related death, and hospitalization in adults with type 2 diabetes and chronic kidney disease.
  • Help control blood sugar in adults with type 2 diabetes.
  • Reduce the risk of serious heart problems like heart attack, stroke, or heart-related death in adults with type 2 diabetes and existing heart disease.
  • Slow kidney disease progression and lower the risk of kidney failure and heart-related death in adults with type 2 diabetes and chronic kidney disease.
Route of Administration Oral Subcutaneous Injection
Side Effects Genital mycotic infections, nasopharyngitis, and urinary tract infections Nausea, vomiting, diarrhea, abdominal pain, and constipation
Dosage and Administration
  • For blood sugar control, the starting dose is 5 mg once daily and can be increased to 10 mg once daily if needed.
  • For all other indications, the recommended dosage is 10 mg once daily.
 Starts with a 0.25 mg weekly injection for four weeks, which may be increased up to a maximum of 2 mg per week.

Efficacy of Farxiga vs. Ozempic

Their effectiveness can vary depending on the approved indications. Here’s a comparison:

For Type 2 Diabetes (T2D)

Multiple studies have demonstrated that Ozempic is more effective than Farxiga in reducing blood sugar levels in adults with type 2 diabetes. A recent study specifically compared these medications based on the diabetes subtype, and results showed that Ozempic led to an 8.2 mmol/mol difference in HbA1c levels than Farxiga.

When analyzing the results by diabetes subtype:

    • Severe Insulin-Deficient Diabetes (SIDD): Participants with SIDD characteristics experienced a 13.4 mmol/mol reduction in HbA1c with Ozempic and only 4.7 mmol/mol with Farxiga.
    • Severe Insulin-Resistant Diabetes (SIRD): Participants with SIRD characteristics saw a 10.5 mmol/mol reduction with Ozempic and only 2.7 mmol/mol with Farxiga.

Additional analyses comparing Ozempic to various SGLT-2 inhibitors found that Ozempic consistently led to greater HbA1c reductions. Specifically, a 1 mg dose of Ozempic lowered HbA1c by 1.11% more than Farxiga 5 mg, reinforcing its superior effectiveness in blood sugar control.

For Cardiovascular Events

Current diabetes treatment guidelines recommend SGLT2 inhibitors or GLP-1RAs for individuals with cardiovascular disease (CVD), as both drug classes have been shown to reduce heart-related risks. However, direct comparisons between Ozempic and Farxiga for cardiovascular conditions are limited.

According to expert recommendations, Ozempic is often preferred over Farxiga for patients at higher risk of stroke. On the other hand, Farxiga has demonstrated greater benefits in reducing the risk of heart failure and is considered a first-line option for heart failure prevention.

Farxiga’s trials showed that while it did not significantly affect major cardiovascular events (MACE), it reduced the risk of hospitalization for heart failure. In contrast, Ozempic’s SUSTAIN-6 trial demonstrated a 26% reduction in MACE risk.

For Chronic Kidney Disease (CKD)

People with T2D and CKD face a high risk of heart failure and premature death from cardiovascular complications. Currently, no studies directly compare Farxiga and Ozempic in slowing CKD progression. However, individual studies have assessed their effects on kidney health.

A study analyzing real-world data from the US and Japan examined how Farxiga impacts CKD progression. Most patients taking Farxiga had moderate to severe CKD (stages 3-4), along with conditions like diabetes, high blood pressure, or cardiovascular disease.

The study found that kidney function declined more slowly in Farxiga users than in those not taking it. This suggests that Farxiga helps slow kidney function deterioration.

In contrast, a real-world study on Ozempic found that after 12 months of treatment, it did not slow kidney function decline, but it also did not worsen. However, there was a 51% reduction in protein levels in the urine (a marker of kidney damage). This suggests that while Ozempic may not slow kidney function loss, it could help protect against further kidney damage.

For Weight Loss

Ozempic has been shown to be more effective than Farxiga for weight loss.

A meta-analysis of patients who were not adequately controlled with one to two oral diabetes medications found that those taking 1 mg of Ozempic lost up to 5.47 lbs more than those taking 5 mg of Farxiga. Another analysis categorized weight loss effects as moderate with Farxiga (3.2%-5% of body weight) and strong with Ozempic (greater than 5%), reinforcing Ozempic’s greater impact on weight reduction.

Medical Insight

A 2024 study evaluated the effectiveness of combining Farxiga and Rybelsus (oral semaglutide) compared to Farxiga alone in real-world patients. The findings showed that patients on the combination therapy had a 1.2% reduction in HbA1c, with 55% reaching near-normal blood sugar levels.

Beyond blood sugar control, the combination also led to greater improvements in weight loss, fasting blood sugar, blood pressure, cholesterol levels, and kidney health markers compared to Farxiga alone.

These results suggest that using both medications together may help some patients achieve near-remission of type 2 diabetes.

Mechanism of Action of Farxiga vs. Ozempic

Farxiga and Ozempic work in different ways to lower blood sugar, support weight loss, and improve overall health.

How Farxiga Works

Farxiga helps control blood sugar by removing excess sugar from the body through the kidneys. Normally, the kidneys filter sugar from the blood but then reabsorb it back into the body. Farxiga blocks this reabsorption, causing sugar to be flushed out through urine instead. This process lowers blood sugar levels without requiring the body to produce more insulin.

Although Farxiga primarily removes glucose (sugar), sodium (salt) is also affected. Since both sodium and glucose are osmotically active molecules, they draw water into the urine. This pulls extra water out of the bloodstream, leading to increased urination (a diuretic effect) and a reduction in fluid buildup in the body.

This effect is part of why Farxiga is beneficial for people with heart failure and kidney disease. By reducing excess fluid, it lightens the workload on the heart and also reduces pressure on the kidneys.

How Ozempic Works

While Farxiga works independently of insulin, Ozempic enhances the body’s natural insulin response. It mimics a hormone called GLP-1, which signals the pancreas to release insulin when blood sugar levels rise. This helps the body use sugar more efficiently, preventing excess sugar from accumulating in the bloodstream.

Additionally, Ozempic slows down how quickly food leaves the stomach, helping people feel full longer and reducing the urge to eat. This mechanism not only supports blood sugar control but also leads to greater weight loss compared to Farxiga.

Although Ozempic does not directly impact fluid balance like Farxiga, it benefits heart health by promoting weight loss and reducing inflammation. Obesity is a major risk factor for cardiovascular diseases, including coronary artery disease, heart failure, and stroke.

Side Effects of Farxiga vs. Ozempic

Senior looking at medication insert

Since Farxiga and Ozempic affect the body differently, so they have distinct side effect profiles.

Farxiga Side Effects

Farxiga increases the amount of sugar in the urine, which can create an environment for infections to develop. This may lead to genital yeast infections and urinary tract infections (UTIs), with the most serious complications being:

    • Urosepsis – A body-wide infection (sepsis) that starts in the urinary tract and can spread throughout the body.
    • Pyelonephritis – A severe form of a UTI that affects the kidneys, usually caused by bacteria traveling from the bladder.
    • Fournier’s Gangrene – A rare but life-threatening bacterial infection affecting the genitals, groin, and perineal area (between the genitals and anus).

Since Farxiga increases urination, it can also lead to volume depletion, which is a loss of fluids and electrolytes from the body. This may cause dizziness, dehydration, and low blood pressure in some individuals.

Other side effects reported in clinical trials include:

    • Nasopharyngitis (common cold symptoms)
    • Back pain
    • Nausea
    • Flu-like symptoms
    • Dyslipidemia (unhealthy fat levels in the blood)
    • Constipation
    • Pain or discomfort while urinating
    • Pain in the arms or legs

Ozempic Side Effects

The most common side effects of Ozempic are gastrointestinal problems, as it slows down digestion to help control blood sugar and appetite. These include:

Though rare, Ozempic has been associated with more severe conditions, just as Farxiga carries risks like Fournier’s gangrene and urinary infections. These are:

    • Pancreatitis – A painful inflammation of the pancreas that can cause severe stomach pain, nausea, and vomiting.
    • Gallbladder Problems – Ozempic may increase the risk of gallstones, which can lead to gallbladder infections or blockages.
    • Kidney Issues – Ozempic may worsen existing kidney disease, particularly in patients who experience dehydration from persistent nausea and vomiting.
    • Thyroid Tumors – In animal studies, semaglutide has been linked to thyroid tumors, though the risk in humans is still being studied.

Other reported side effects include:

    • Dizziness
    • Fatigue
    • Injection site reactions
    • Reflux or heartburn

Additionally, both Farxiga and Ozempic can increase the risk of hypoglycemia (low blood sugar), especially when combined with insulin or an insulin-releasing medication.

Approved Indications of Farxiga vs. Ozempic

Ozempic and Farxiga are both FDA-approved for managing type 2 diabetes, but they have different additional indications based on their effects on the body.

Ozempic (Semaglutide)

  • Approved as an add-on to diet and exercise to improve blood sugar control in adults with type 2 diabetes.
  • Approved to reduce the risk of major cardiovascular events (heart attack, stroke, cardiovascular death) in adults with type 2 diabetes and existing heart disease.
  • Approved to slow the progression of kidney disease and reduce the risk of kidney failure and cardiovascular death in adults with type 2 diabetes and CKD.
  • Not FDA-approved for heart failure.
  • Not FDA-approved for weight loss under the Ozempic brand, but semaglutide (same active ingredient) is approved for weight loss under the Wegovy brand.

Farxiga (Dapagliflozin)

  • Approved as an add-on to diet and exercise to improve blood sugar control in patients aged 10 years and older with type 2 diabetes.
  • Approved to slow the progression of kidney disease and reduce the risk of kidney failure, cardiovascular death, and hospitalization in adults with CKD at risk of progression (with or without diabetes).
  • Approved to reduce the risk of hospitalization for heart failure and urgent heart failure visits in adults with heart failure (with or without diabetes).
  • Not FDA-approved for MACE reduction, though approved to reduce the risk of cardiovascular death in adults with heart failure or CKD (with or without diabetes).
  • Not FDA-approved for weight loss, though it may lead to modest weight loss as a side effect.

These drugs also have specific usage limitations:

    • Ozempic and Farxiga are not recommended for type 1 diabetes. However, a recent study suggests that Ozempic may help improve glucose levels in people with type 1 diabetes using automated pumps, without increasing the risk of hypoglycemia.
    • Farxiga should not be used for type 2 diabetes in patients with an eGFR below 45 mL/min/1.73 m², as it is unlikely to be effective.
    • Farxiga is not recommended for chronic kidney disease in patients with polycystic kidney disease or those recently treated with immunosuppressive therapy, as it is not expected to provide benefits.

Dosage and Administration of Farxiga vs. Ozempic

Here’s a comparison of the dosage and administration for Ozempic and Farxiga:
Parameter Ozempic Dosage Farxiga Dosage
Route of Administration Subcutaneous injection (once weekly) Oral tablet (once daily)
Starting Dose 0.25 mg once weekly for 4 weeks 5 mg once daily
Maintenance Dose 0.5 mg once weekly, can increase to 1 mg or 2 mg if needed 10 mg once daily
Timing with Food Can be taken anytime, with or without food Can be taken anytime, with or without food
Missed Dose Take within 5 days, otherwise skip and continue on schedule Take as soon as remembered, but do not double the dose
Surgery/Fasting Precaution Patients taking Ozempic should inform their doctor before undergoing surgery or any procedure that requires general anesthesia or deep sedation. Stop at least 3 days before major surgery

Cost of Farxiga vs. Ozempic

The cost of Farxiga and Ozempic varies depending on factors like insurance coverage, pharmacy pricing, and available discounts.

Farxiga is the more affordable option, with a list price of $599.72 for a 30-day supply. It also has a generic version (dapagliflozin) available in the US, potentially lowering costs further. In contrast, Ozempic does not yet have a generic version and is priced higher, at $997.58 for a one-month supply.

Get Your Diabetes Medications from Pharma Giant!

If you’re searching for a more affordable way to access Farxiga and Ozempic, Pharma Giant, a trusted online Canadian pharmacy partner, provides a cost-effective and convenient solution.

At Pharma Giant, Farxiga starts at $31.99, and Ozempic starts at $329.95. Save even more with coupons, bulk orders, and an exclusive 10% discount for new customers using the code PGSAVE10.

Summary

Ozempic is more effective than Farxiga for lowering blood sugar and promoting weight loss. It also reduces major cardiovascular events, making it a better choice for stroke prevention. Farxiga, however, is better for heart failure and kidney disease, helping to slow kidney function decline and reduce hospitalizations.

Farxiga is taken as a daily pill, while Ozempic requires a weekly injection. Their side effects differ. Farxiga increases the risk of UTIs and dehydration, while Ozempic commonly causes nausea and digestive issues.

Farxiga is more affordable, with a generic version available, whereas Ozempic remains expensive. Choosing between them depends on specific health needs and should be discussed with a doctor.

Frequently Asked Questions

The cost of Farxiga with Medicare varies depending on your specific plan, coverage stage, and pharmacy. On average, the out-of-pocket cost of government-insured people with Medicare Part D is $38.82 per month.

Farxiga and weight loss are linked because the medication helps remove excess sugar through urine, leading to calorie loss and mild weight reduction. Studies show that people taking Farxiga may lose around 3-5% of their body weight over time. However, Farxiga is not FDA-approved for weight loss and is primarily prescribed for type 2 diabetes, heart failure, and chronic kidney disease.

Farxiga can be taken at any time of day, but it is typically recommended to take it in the morning, once daily, with or without food. Taking it in the morning may help manage its diuretic effect (increased urination) throughout the day and reduce the risk of dehydration at night. Always follow your doctor’s instructions on when to take it.

Jardiance and Ozempic work differently to manage type 2 diabetes and provide heart benefits. In a meta-analysis, Ozempic lowered HbA1c more than Jardiance, with a 0.61% greater reduction. Ozempic also led to greater weight loss, with patients losing an average of 3.6 lbs more than those on Jardiance. However, since this was not a direct head-to-head trial, the results should be interpreted cautiously.

Yes, Farxiga may cause modest weight loss, typically around 3-5% of body weight over time. This occurs because Farxiga removes excess sugar through urine, leading to calorie loss. However, Farxiga is not FDA-approved for weight loss, and the weight reduction is usually less than what is seen with GLP-1 medications like Saxenda or Wegovy.

Alternatives to Farxiga include other SGLT2 inhibitors and different classes of diabetes medications, such as Jardiance (empagliflozin), Invokana (canagliflozin), Steglatro (ertugliflozin), GLP-1 receptor agonists (Ozempic, Trulicity, or Mounjaro), and metformin.

Farxiga and Metformin work differently, and neither is inherently “better.” They are often used together as part of a combination therapy. A real-world study found that adding Farxiga to metformin led to significant improvements in blood sugar levels (1.1% reduction), weight (3.1 lbs lost), BMI, and blood pressure in patients with uncontrolled type 2 diabetes.

Farxiga lowers blood sugar levels by preventing the kidneys from reabsorbing glucose, which causes excess sugar to be excreted in urine. In addition to improving blood sugar control in type 2 diabetes, it also reduces the risk of hospitalization for heart failure, slows the progression of chronic kidney disease, and may lead to modest weight loss.

When comparing Farxiga vs. Ozempic, semaglutide (Ozempic, a GLP-1 RA) generally produces larger reductions in A1C and weight than SGLT2 inhibitors like dapagliflozin. For heart failure or CKD protection, SGLT2 inhibitors are first-line per guidelines, with strong outcome data. Many patients benefit from one or the other based on comorbidities.

Related Articles

Sources

Dwibedi, C., Ekström, O., Brandt, J., Adiels, M., Franzén, S., Abrahamsson, B., & Rosengren, A. H. (2024). Randomized open-label trial of semaglutide and dapagliflozin in patients with type 2 diabetes of different pathophysiology. Nature metabolism, 6(1), 50–60. https://doi.org/10.1038/s42255-023-00943-3

Sharma, R., Wilkinson, L., Vrazic, H., Popoff, E., Lopes, S., Kanters, S., & Druyts, E. (2018). Comparative efficacy of once-weekly semaglutide and SGLT-2 inhibitors in type 2 diabetic patients inadequately controlled with metformin monotherapy: a systematic literature review and network meta-analysis. Current Medical Research and Opinion, 34(9), 1595–1603. https://doi.org/10.1080/03007995.2018.1476332

Marso, S. P., Bain, S. C., Consoli, A., Eliaschewitz, F. G., Jódar, E., Leiter, L. A., Lingvay, I., Rosenstock, J., Seufert, J., Warren, M. L., Woo, V., Hansen, O., Holst, A. G., Pettersson, J., & Vilsbøll, T. (2016). Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes. New England Journal of Medicine, 375(19), 1834–1844. https://doi.org/10.1056/nejmoa1607141

Rolek, B., Haber, M., Gajewska, M., Rogula, S., Pietrasik, A., & G?secka, A. (2023). SGLT2 Inhibitors vs. GLP-1 Agonists to Treat the Heart, the Kidneys and the Brain. Journal of cardiovascular development and disease, 10(8), 322. https://doi.org/10.3390/jcdd10080322

Wiviott, S. D., Raz, I., Bonaca, M. P., Mosenzon, O., Kato, E. T., Cahn, A., Silverman, M. G., Zelniker, T. A., Kuder, J. F., Murphy, S. A., Bhatt, D. L., Leiter, L. A., McGuire, D. K., Wilding, J. P. H., Ruff, C. T., Gause-Nilsson, I. A. M., Fredriksson, M., Johansson, P. A., Langkilde, A. M., Sabatine, M. S., … DECLARE–TIMI 58 Investigators (2019). Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes. The New England journal of medicine, 380(4), 347–357. https://doi.org/10.1056/NEJMoa1812389

Aviles Bueno, B., Soler, M. J., Perez-Belmonte, L., Jimenez Millan, A., Rivas Ruiz, F., & Garcia de Lucas, M. D. (2022). Semaglutide in type 2 diabetes with chronic kidney disease at high risk progression-real-world clinical practice. Clinical kidney journal, 15(8), 1593–1600. https://doi.org/10.1093/ckj/sfac096

Tangri, N., Rastogi, A., Nekeman-Nan, C., Hong, L. S., Ozaki, A., Franzén, S., & Sofue, T. (2024). Dapagliflozin Utilization in Chronic Kidney Disease and Its Real-World Effectiveness Among Patients with Lower Levels of Albuminuria in the USA and Japan. Advances in therapy, 41(3), 1151–1167. https://doi.org/10.1007/s12325-023-02773-x

Lunati, M. E., Cimino, V., Bernasconi, D., Gandolfi, A., Morpurgo, P. S., Tinari, C., Lazzaroni, E., Baruffaldi, L., Muratori, M., Montefusco, L., Pastore, I., Rossi, A., Franzetti, I. G., Muratori, F., Manfrini, R., Disoteo, O. E., Terranova, R., Desenzani, P., Girelli, A., . . . Fiorina, P. (2023). Type 2 diabetes mellitus pharmacological remission with dapagliflozin plus oral semaglutide. Pharmacological Research, 199, 107040. https://doi.org/10.1016/j.phrs.2023.107040

Kanters, S., Wilkinson, L., Vrazic, H., Sharma, R., Lopes, S., Popoff, E., & Druyts, E. (2019). Comparative efficacy of once-weekly semaglutide versus SGLT-2 inhibitors in patients inadequately controlled with one to two oral antidiabetic drugs: a systematic literature review and network meta-analysis. BMJ open, 9(7), e023458. https://doi.org/10.1136/bmjopen-2018-023458

Lazzaroni, E., Nasr, M. B., Loretelli, C., Pastore, I., Plebani, L., Lunati, M. E., Vallone, L., Bolla, A. M., Rossi, A., Montefusco, L., Ippolito, E., Berra, C., D’Addio, F., Zuccotti, G. V., & Fiorina, P. (2021). Anti-diabetic drugs and weight loss in patients with type 2 diabetes. Pharmacological Research, 171, 105782. https://doi.org/10.1016/j.phrs.2021.105782

Akil, L., & Ahmad, H. A. (2011). Relationships between obesity and cardiovascular diseases in four southern states and Colorado. Journal of health care for the poor and underserved, 22(4 Suppl), 61–72. https://doi.org/10.1353/hpu.2011.0166

Pasqua, M., Tsoukas, M. A., Kobayati, A., Aboznadah, W., Jafar, A., & Haidar, A. (2025b). Subcutaneous weekly semaglutide with automated insulin delivery in type 1 diabetes: a double-blind, randomized, crossover trial. Nature Medicine. https://doi.org/10.1038/s41591-024-03463-z

Lingvay, I., Capehorn, M. S., Catarig, A. M., Johansen, P., Lawson, J., Sandberg, A., Shaw, R., & Paine, A. (2020). Efficacy of Once-Weekly Semaglutide vs Empagliflozin Added to Metformin in Type 2 Diabetes: Patient-Level Meta-analysis. The Journal of clinical endocrinology and metabolism, 105(12), e4593–e4604. https://doi.org/10.1210/clinem/dgaa577

Sethi, B., Sahay, R., Tiwaskar, M., Negalur, V., Dhediya, R., Gaurav, K., Rathod, R., Kotak, B., Dhanaki, G., & Shah, S. (2024). Effectiveness of Dapagliflozin as Add-On to Metformin with or without Other Oral Antidiabetic Drugs in Type 2 Diabetes Mellitus: A Multicentre, Retrospective, Real-World Database Study. Drugs – real world outcomes, 11(1), 81–90. https://doi.org/10.1007/s40801-023-00398-8

AstraZeneca Pharmaceuticals LP. (2024). HIGHLIGHTS OF PRESCRIBING INFORMATION OF FARXIGA. Retrieved from https://den8dhaj6zs0e.cloudfront.net/50fd68b9-106b-4550-b5d0-12b045f8b184/0be9cb1b-3b33-41c7-bfc2-04c9f718e442/0be9cb1b-3b33-41c7-bfc2-04c9f718e442_viewable_rendition__v.pdf

Novo Nordisk Inc. (2025). HIGHLIGHTS OF PRESCRIBING INFORMATION OF OZEMPIC. Retrieved from https://www.novo-pi.com/ozempic.pdf